FDA Approves First Anti-Diarrheal Drug for HIV/AIDS Patients
FDA Approves First Anti-Diarrheal Drug for HIV/AIDS Patients
Filed under: drug treatment programs maryland
In 2006, the FDA approved the first botanical prescription drug, Veregen (sinecatechins), a treatment for external genital and perianal warts. "Currently, there are no FDA-approved therapies for HIV-associated diarrhea," said Julie Beitz, M.D …
Read more on Equities.com
Viamet Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare …
Filed under: drug treatment programs maryland
RESEARCH TRIANGLE PARK, N.C., Jan 03, 2013 (BUSINESS WIRE) — Viamet Pharmaceuticals, Inc., a world leader in the development of best-in-class therapies targeting metalloenzymes, announced today that Robert Schotzinger, M.D., Ph.D., President and CEO …
Read more on MarketWatch (press release)
A Call to Eliminate 'Chemotherapy Concession'
Filed under: drug treatment programs maryland
A new study confirms that financial incentives exist for some US oncologists in the prescribing of chemotherapy and growth factors for treatment-related anemia. These potential "inducements" are not widespread, existing for only about 25% of …
Read more on Medscape
Allison brings immunotherapy expertise to MD Anderson – Opportunity to combine immune therapies with targeted cancer drugs attracts scientist to MD Anderson. “It’s a chance to move to a place where things are really happening.” “The main reason for coming to MD Anderson is the opportunity offered by a clinical community that’s open to using immunological approaches to treat cancer combined with other therapies,” Allison said. “We plan to build a large platform where basic scientists interested in mouse models of cancer work side-by-side with physician-scientists who treat patients to analyze tissues from those patients and truly understand the mechanisms involved,” Allison said. “We can accelerate the transition of new combinations of drugs into the clinic beyond phase I clinical trials and broaden our focus beyond melanoma and prostate cancer to other types of cancer. “We all know that no single drug will cure cancer. I think this is where we’ll start getting cures, or at least long-term survival of patients. There’s lots of enthusiasm for this approach at MD Anderson and I’m really excited about it,” he said. Allison will play an instrumental role in MD Anderson’s recently announced Moon Shots Program to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. He is a member of the National Academy of Sciences and the Institute of Medicine, as well as a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. He …